<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552602</url>
  </required_header>
  <id_info>
    <org_study_id>REGPHD2015</org_study_id>
    <nct_id>NCT02552602</nct_id>
  </id_info>
  <brief_title>The Role of Multivitamins in Pediatric HIV Management in Nigeria</brief_title>
  <official_title>The Role of Multivitamins in Pediatric HIV Management in Nigeria: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regina Esiovwa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of the West of Scotland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brunel Healthcare Manufacturing Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Partec Nigeria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Panets Education Trust for Africa (PETA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lagos State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nigerian Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scottish Trace Element and Micronutrient Diagnostic and Research Laboratory, Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of the West of Scotland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Micronutrient deficiencies in people living with HIV have been reported. Multivitamins can
      address micronutrient deficiencies, however the benefits of multivitamins in people living
      with HIV is still debatable. While some multivitamin intervention studies have reported the
      benefits of multivitamins in HIV infection, some other studies have reported no statistical
      differences in outcomes of interest in intervention and control groups. With clear
      differences in composition and strength of the multivitamins used in the different studies,
      it is possible that some of the multivitamins used in some of the intervention studies may
      have been unable to meet existing micronutrient deficiencies. Hence there is a chance that
      higher strength multivitamins may be better able to correct these deficiencies and result in
      better outcomes. This study will therefore compare three different multivitamins varying in
      strength and composition to determine if any one of the three multivitamins will produce
      better health outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The link between micronutrient deficiencies and advanced HIV disease has been reported.
      Micronutrient deficiencies in people living with HIV/AIDS (PLWHA) have been linked to reduced
      antioxidant levels and oxidative stress. In turn oxidative stress is believed to promote HIV
      disease progression. The use of multivitamins in PLWHA therefore has the potential to cut off
      the interconnections between micronutrient deficiencies and HIV disease progression. If
      beneficial, multivitamin use in PLWHA could result in improved health outcomes.

      A number of studies have explored this possibility with different results. Differences in
      multivitamin strength and composition could have been responsible for the different results.
      Therefore, it is likely that increasing the strength and composition of the intervention
      multivitamin could possibly produce a single result of improved health outcomes across board.
      Hence this study will determine if multivitamins at higher strength can cause better health
      outcomes in study participants compared to lower strength multivitamins.

      Multivitamin A is composed of 7 vitamins at recommended daily allowance (RDA), multivitamin B
      is made up of 22 micronutrients at RDA and multivitamin C is made up of 22 micronutrients at
      3 times the RDA. These multivitamins were administered to the 190 study participants in a
      double blind randomized controlled study to determine if there would be any significant
      differences in health outcome of participants after 6 months of multivitamin use. All
      multivitamins regardless of their composition were manufactured to look identical and
      packaged in identical containers.

      This double blind randomized controlled study is being conducted at the HIV treatment centers
      of the Nigerian Institute of Medical Research and the Lagos State University Teaching
      Hospital, both in Lagos Nigeria. At the design stage of the study, a feasibility study was
      carried out at both HIV treatment centers to assess the practicability and potential of
      success for this study. Following a successful feasibility study, ethical approval was
      applied for and obtained from each institution.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4 count</measure>
    <time_frame>6 months</time_frame>
    <description>A measure of immune competence. CD4 count could range from 500-1500 cells/mm3. Lower values can be seen with advancing HIV disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum selenium levels</measure>
    <time_frame>6 months</time_frame>
    <description>To measure selenium deficiency. Range of 70µg/L -100µg/L have been proposed to describe adequacy of selenium levels in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum zinc levels</measure>
    <time_frame>6 months</time_frame>
    <description>To determine levels of zinc deficiency. 80µg/dL is often used as a cutoff point to signify deficiency in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum vitamin A levels</measure>
    <time_frame>6 months</time_frame>
    <description>To determine vitamin A deficiency using cut off point of 0.7µmol/L for participants 5-6 years and 0.9µmol/L for participants 7-12 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red cell vitamin B6 levels</measure>
    <time_frame>6 months</time_frame>
    <description>To identify B6 deficiency. 250-680 pmol/g haemoglobin will be the reference range used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Copper levels</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate copper deficiency. 12.5 to 22μmol/L will be the reference range used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red cell manganese levels</measure>
    <time_frame>6 months</time_frame>
    <description>To determine deficiency. Reference range not yet established</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red cell Magnesium</measure>
    <time_frame>6 months</time_frame>
    <description>To determine deficiency levels. Reference range of 5.80-8.55 μmol/g haemoglobin will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum vitamin E levels</measure>
    <time_frame>6 months</time_frame>
    <description>To determine deficiency. Reference range of 3.5 - 9.5 μmol/mmol cholesterol will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red cell selenium levels</measure>
    <time_frame>6 months</time_frame>
    <description>To measure selenium deficiency.3.6 - 10.6 nmol/g haemoglobin will be the reference range used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red cell zinc levels</measure>
    <time_frame>6 months</time_frame>
    <description>To determine zinc deficiency. 423-781 nmol/g haemoglobin will be the reference range used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red cell Copper levels</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate copper deficiency. 27.9-53.4 nmol/g haemoglobin will be the reference range used</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hemoglobin (g/dl)</measure>
    <time_frame>6 months</time_frame>
    <description>As part of routine tests</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Alanine aminotransferase (ALT) levels (U/L)</measure>
    <time_frame>6 months</time_frame>
    <description>As part of routine tests</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Aspartate aminotransferase (AST) levels (IU/L)</measure>
    <time_frame>6 months</time_frame>
    <description>As part of routine tests</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Bilirubin levels (mg/dl)</measure>
    <time_frame>6 months</time_frame>
    <description>As part of routine tests</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Albumin levels (g/dl)</measure>
    <time_frame>6 months</time_frame>
    <description>As part of routine tests</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Creatinine levels (mg/dl)</measure>
    <time_frame>6 months</time_frame>
    <description>As part of routine tests</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Urea levels (mg/dl)</measure>
    <time_frame>6 months</time_frame>
    <description>As part of routine tests</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum C- Reactive Protein levels (mg/L)</measure>
    <time_frame>6 months</time_frame>
    <description>As part of routine tests</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participants in this arm will be given Multivitamin A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participants in this arm will be given Multivitamin B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participants in this arm will be given Multivitamin C</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multivitamin A</intervention_name>
    <description>Multivitamin containing 7 micronutrients at recommended daily allowance (RDA)</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multivitamin B</intervention_name>
    <description>Multivitamin containing 22 micronutrients at RDA</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multivitamin C</intervention_name>
    <description>Multivitamin containing 22 micronutrients at three times the RDA</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children aged 5 - 12 years attending the outpatient clinic of the two HIV treatment
             centers who have tested positive to HIV

          2. Children who can return for follow up during the 6 months of the study

          3. Children with guardians who can give informed consent -

        Exclusion Criteria:

          1. Children enrolled in other studies

          2. Guardians and children anticipating moving away from the study state

          3. Children receiving immunosuppressive therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Regina Esiovwa</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of the West of Scotland</affiliation>
  </overall_official>
  <reference>
    <citation>Akiibinu, M., Adeshiyan, A. and Olalekan, A. (2012) 'Micronutrients and markers of oxidative stress in symptomatic HIV positive/AIDS Nigerians: A call for adjuvant micronutrients therapy', The IIOAB Journal, 3, pp. 7-11.</citation>
  </reference>
  <reference>
    <citation>Baum MK, Campa A, Lai S, Sales Martinez S, Tsalaile L, Burns P, Farahani M, Li Y, van Widenfelt E, Page JB, Bussmann H, Fawzi WW, Moyo S, Makhema J, Thior I, Essex M, Marlink R. Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral-naive, HIV-infected adults in Botswana: a randomized clinical trial. JAMA. 2013 Nov 27;310(20):2154-63. doi: 10.1001/jama.2013.280923.</citation>
    <PMID>24281460</PMID>
  </reference>
  <reference>
    <citation>Bhandari S, Banjara MR. Micronutrients Deficiency, a Hidden Hunger in Nepal: Prevalence, Causes, Consequences, and Solutions. Int Sch Res Notices. 2015 Jan 15;2015:276469. doi: 10.1155/2015/276469. eCollection 2015. Review.</citation>
    <PMID>27347513</PMID>
  </reference>
  <reference>
    <citation>Bunupuradah T, Ubolyam S, Hansudewechakul R, Kosalaraksa P, Ngampiyaskul C, Kanjanavanit S, Wongsawat J, Luesomboon W, Pinyakorn S, Kerr S, Ananworanich J, Chomtho S, van der Lugt J, Luplertlop N, Ruxrungtham K, Puthanakit T; PREDICT study group. Correlation of selenium and zinc levels to antiretroviral treatment outcomes in Thai HIV-infected children without severe HIV symptoms. Eur J Clin Nutr. 2012 Aug;66(8):900-5. doi: 10.1038/ejcn.2012.57. Epub 2012 Jun 20.</citation>
    <PMID>22713768</PMID>
  </reference>
  <reference>
    <citation>Drain PK, Kupka R, Mugusi F, Fawzi WW. Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy. Am J Clin Nutr. 2007 Feb;85(2):333-45. Review.</citation>
    <PMID>17284727</PMID>
  </reference>
  <reference>
    <citation>Fawzi WW, Msamanga GI, Spiegelman D, Wei R, Kapiga S, Villamor E, Mwakagile D, Mugusi F, Hertzmark E, Essex M, Hunter DJ. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med. 2004 Jul 1;351(1):23-32.</citation>
    <PMID>15229304</PMID>
  </reference>
  <reference>
    <citation>Guwatudde D, Wang M, Ezeamama AE, Bagenda D, Kyeyune R, Wamani H, Manabe YC, Fawzi WW. The effect of standard dose multivitamin supplementation on disease progression in HIV-infected adults initiating HAART: a randomized double blind placebo-controlled trial in Uganda. BMC Infect Dis. 2015 Aug 19;15:348. doi: 10.1186/s12879-015-1082-x.</citation>
    <PMID>26285704</PMID>
  </reference>
  <reference>
    <citation>Kaiser JD, Campa AM, Ondercin JP, Leoung GS, Pless RF, Baum MK. Micronutrient supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral therapy: a prospective, double-blinded, placebo-controlled trial. J Acquir Immune Defic Syndr. 2006 Aug 15;42(5):523-8.</citation>
    <PMID>16868496</PMID>
  </reference>
  <reference>
    <citation>Kupka R, Msamanga GI, Spiegelman D, Morris S, Mugusi F, Hunter DJ, Fawzi WW. Selenium status is associated with accelerated HIV disease progression among HIV-1-infected pregnant women in Tanzania. J Nutr. 2004 Oct;134(10):2556-60.</citation>
    <PMID>15465747</PMID>
  </reference>
  <reference>
    <citation>Monteiro JP, Cruz ML, Mussi-Pinhata MM, Salomão RG, Jordão Junior A, Read JS, Pilotto JH, Cohen RA, Stoszek SK, Siberry GK. Vitamin A, vitamin E, iron and zinc status in a cohort of HIV-infected mothers and their uninfected infants. Rev Soc Bras Med Trop. 2014 Nov-Dec;47(6):692-700. doi: 10.1590/0037-8682-0226-2014.</citation>
    <PMID>25626647</PMID>
  </reference>
  <reference>
    <citation>Ndeezi G, Tylleskär T, Ndugwa CM, Tumwine JK. Effect of multiple micronutrient supplementation on survival of HIV-infected children in Uganda: a randomized, controlled trial. J Int AIDS Soc. 2010 Jun 3;13:18. doi: 10.1186/1758-2652-13-18.</citation>
    <PMID>20525230</PMID>
  </reference>
  <reference>
    <citation>Nkengfack GN, Torimiro JN, Englert H. Effects of antioxidants on CD4 and viral load in HIV-infected women in sub-Saharan Africa - dietary supplements vs. local diet. Int J Vitam Nutr Res. 2012 Feb;82(1):63-72. doi: 10.1024/0300-9831/a000095. Review.</citation>
    <PMID>22811378</PMID>
  </reference>
  <reference>
    <citation>Pugliese C, Patin RV, Palchetti CZ, Claudio CC, Gouvêa Ade F, Succi RC, Amancio OM, Cozzolino SM, Oliveira FL. Assessment of antioxidants status and superoxide dismutase activity in HIV-infected children. Braz J Infect Dis. 2014 Sep-Oct;18(5):481-6. doi: 10.1016/j.bjid.2014.02.003. Epub 2014 Apr 26.</citation>
    <PMID>24780364</PMID>
  </reference>
  <reference>
    <citation>Semba RD, Tang AM. Micronutrients and the pathogenesis of human immunodeficiency virus infection. Br J Nutr. 1999 Mar;81(3):181-9. Review.</citation>
    <PMID>10434844</PMID>
  </reference>
  <reference>
    <citation>Semeere AS, Nakanjako D, Ddungu H, Kambugu A, Manabe YC, Colebunders R. Sub-optimal vitamin B-12 levels among ART-naïve HIV-positive individuals in an urban cohort in Uganda. PLoS One. 2012;7(7):e40072. doi: 10.1371/journal.pone.0040072. Epub 2012 Jul 2.</citation>
    <PMID>22768330</PMID>
  </reference>
  <reference>
    <citation>Sharma B. Oxidative stress in HIV patients receiving antiretroviral therapy. Curr HIV Res. 2014;12(1):13-21. Review.</citation>
    <PMID>24694264</PMID>
  </reference>
  <reference>
    <citation>Shin DH, Martinez SS, Parsons M, Jayaweera DT, Campa A, Baum MK. Relationship of Oxidative Stress with HIV Disease Progression in HIV/HCV Co-infected and HIV Mono-infected Adults in Miami. Int J Biosci Biochem Bioinforma. 2012;2(3):217-223.</citation>
    <PMID>23504530</PMID>
  </reference>
  <reference>
    <citation>Shivakoti R, Christian P, Yang WT, Gupte N, Mwelase N, Kanyama C, Pillay S, Samaneka W, Santos B, Poongulali S, Tripathy S, Riviere C, Berendes S, Lama JR, Cardoso SW, Sugandhavesa P, Tang AM, Semba RD, Campbell TB, Gupta A; NWCS 319 and PEARLS Study Team. Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults. Clin Nutr. 2016 Feb;35(1):183-9. doi: 10.1016/j.clnu.2015.02.002. Epub 2015 Feb 10.</citation>
    <PMID>25703452</PMID>
  </reference>
  <reference>
    <citation>Singh G, Pai RS. Dawn of antioxidants and immune modulators to stop HIV-progression and boost the immune system in HIV/AIDS patients: An updated comprehensive and critical review. Pharmacol Rep. 2015 Jun;67(3):600-5. doi: 10.1016/j.pharep.2014.12.007. Epub 2014 Dec 24. Review.</citation>
    <PMID>25933975</PMID>
  </reference>
  <reference>
    <citation>UNICEF (2006) Preventing and controlling micronutrient deficiencies in populations affected by an emergency. Available at: http://www.unicef.org/nutrition/files/Joint_Statement_Micronutrients_March_2006.pdf (Accessed: 5 September 2015).</citation>
  </reference>
  <reference>
    <citation>Visser ME, Maartens G, Kossew G, Hussey GD. Plasma vitamin A and zinc levels in HIV-infected adults in Cape Town, South Africa. Br J Nutr. 2003 Apr;89(4):475-82.</citation>
    <PMID>12654165</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>September 16, 2015</last_update_submitted>
  <last_update_submitted_qc>September 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of the West of Scotland</investigator_affiliation>
    <investigator_full_name>Regina Esiovwa</investigator_full_name>
    <investigator_title>PhD Student</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Multivitamins</keyword>
  <pending_results>
    <submitted>October 17, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

